Back to top
more

Organigram Global Inc. (OGI)

(Delayed Data from NSDQ)

$1.38 USD

1.38
394,880

0.00 (0.00%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.39 +0.01 (0.72%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OrganiGram (OGI) Surges: Stock Moves 8.9% Higher

by Zacks Equity Research

OrganiGram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Equity Research

Will OrganiGram (OGI) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Nike, OrganiGram, Thermo Fisher, Danaher Corp and Agilent Tech highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Nike, OrganiGram, Thermo Fisher, Danaher Corp and Agilent Tech highlighted as Zacks Bull and Bear of the Day

Madeleine Johnson headshot

Bear of the Day: OrganiGram Holdings (OGI)

by Madeleine Johnson

Revenue and profits have fallen significantly year-over-year for this cannabis stock.

Zacks Equity Research

New Strong Sell Stocks for September 11th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Zacks Equity Research

OrganiGram (OGI) Reports Break-Even Earnings for Q3

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of 100.00% and -20.81%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrganiGram (OGI) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and product launches in the fiscal third quarter despite pandemic-hit business conditions.

Zacks Equity Research

Do Options Traders Know Something About Organigram (OGI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Organigram (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

Organigram (OGI) Catches Eye: Stock Jumps 11.7%

by Zacks Equity Research

Organigram (OGI) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Zacks Equity Research

OrganiGram (OGI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of -100.00% and -15.60%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Product Innovation Aid OrganiGram (OGI) in Q2 Earnings?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and ongoing product innovation in the fiscal second quarter.

Zacks Equity Research

Implied Volatility Surging for Organigram (OGI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Organigram Holdings (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

Options Traders Expect Huge Moves in OrganiGram (OGI) Stock

by Zacks Equity Research

Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Zacks Equity Research

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

by Zacks Equity Research

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Zacks Equity Research

Why Earnings Season Could Be Great for OrganiGram (OGI)

by Zacks Equity Research

OrganiGram (OGI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Implied Volatility Surging for OrganiGram (OGI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

What's in the Cards for OrganiGram (OGI) in Q4 Earnings?

by Zacks Equity Research

According to OrganiGram (OGI), there is hugely unmet consumer demand for CBD products.

Tirthankar Chakraborty headshot

Marijuana Stocks to Buy or Avoid in November

by Tirthankar Chakraborty

We highlight three marijuana stocks that look like solid bargains, while one in particular should be avoided in the near future.

Zacks Equity Research

LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View

by Zacks Equity Research

LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.

Zacks Equity Research

Organigram (OGI) Catches Eye: Stock Jumps 8.6%

by Zacks Equity Research

Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Equity Research

Options Traders Expect Huge Moves in OrganiGram (OGI) Stock

by Zacks Equity Research

Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.

Neena Mishra headshot

Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF

by Neena Mishra

CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.

Neena Mishra headshot

Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF

by Neena Mishra

CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.